| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,845,860 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
49,676 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$85,601 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
7 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,545 |
91,132 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-02-26 |
4 |
D |
$3.22 |
$64,545 |
D/D |
(20,045) |
1,277,380 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,767 |
1,297,425 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2022-02-26 |
4 |
D |
$3.22 |
$34,660 |
D/D |
(10,764) |
33,373 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2022-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,545 |
44,137 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2022-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,667 |
868,458 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2022-01-19 |
4 |
AS |
$4.27 |
$8,540 |
D/D |
(2,000) |
57,305 |
|
-53% |
|
| Benito Simon X |
Director |
– • – |
2022-01-19 |
4 |
OE |
$2.20 |
$4,400 |
D/D |
2,000 |
59,305 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2022-01-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,274 |
17,248 |
|
- |
|
| Zoth Lota S |
Director |
– • – |
2022-01-05 |
4 |
AS |
$5.01 |
$4,815 |
D/D |
(961) |
25,016 |
|
-60% |
|
| Zoth Lota S |
Director |
– • – |
2022-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,090 |
25,977 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2021-08-09 |
4 |
AS |
$9.15 |
$94,401 |
D/D |
(10,317) |
68,587 |
|
-38% |
|
| Kies Peter |
CFO |
• – – |
2021-06-09 |
4 |
AS |
$10.01 |
$337,838 |
D/D |
(33,750) |
130,788 |
|
-30% |
|
| Kies Peter |
CFO |
• – – |
2021-06-09 |
4 |
OE |
$2.16 |
$29,700 |
D/D |
13,750 |
164,538 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2021-06-09 |
4 |
AS |
$9.07 |
$93,584 |
D/D |
(10,318) |
78,904 |
|
-30% |
|
| Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2021-06-09 |
4 |
AS |
$10.01 |
$385,735 |
D/D |
(38,535) |
21,592 |
|
-30% |
|
| Kies Peter |
CFO |
• – – |
2021-06-03 |
4 |
AS |
$8.03 |
$80,300 |
D/D |
(10,000) |
150,788 |
|
-14% |
|
| Weiner David B. |
Director |
– • – |
2021-05-17 |
4 |
AS |
$6.62 |
$20,158 |
D/D |
(3,045) |
856,791 |
|
14% |
|
| Benito Simon X |
Director |
– • – |
2021-05-17 |
4 |
AS |
$6.62 |
$20,158 |
D/D |
(3,045) |
57,305 |
|
14% |
|
| Zoth Lota S |
Director |
– • – |
2021-05-17 |
4 |
AS |
$6.62 |
$13,538 |
D/D |
(2,045) |
21,887 |
|
14% |
|
| Miller Ann Calby |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,700 |
25,261 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,700 |
859,836 |
|
- |
|
| Yarno Wendy L |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,700 |
37,153 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,700 |
60,350 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2021-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,700 |
12,974 |
|
- |
|
488 Records found
|
|
Page 4 of 20 |
|
|
